Malcolm A. Leissring, Ph.D. - Publications

2000 University of California, Irvine, Irvine, CA 

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE. Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition In Vitro. Endocrinology. en20161410. PMID 27404391 DOI: 10.1210/en.2016-1410  0.88
2015 Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ. Age and Its Association with Low Insulin and High Amyloid-β Peptides in Blood. Journal of Alzheimer's Disease : Jad. PMID 26444783 DOI: 10.3233/JAD-150428  0.88
2015 Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, ... ... Leissring MA, et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. Acs Chemical Biology. PMID 26398879 DOI: 10.1021/acschembio.5b00334  0.88
2014 Leissring MA. Aβ degradation-the inside story. Frontiers in Aging Neuroscience. 6: 229. PMID 25206334 DOI: 10.3389/fnagi.2014.00229  0.88
2014 Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 511: 94-8. PMID 24847884 DOI: 10.1038/nature13297  0.88
2014 Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA. The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et MéTabolisme. 46: 73-4. PMID 23975847 DOI: 10.1055/s-0033-1353211  0.88
2013 Leissring MA, Turner AJ. Regulation of distinct pools of amyloid β-protein by multiple cellular proteases. Alzheimer's Research & Therapy. 5: 37. PMID 23953275 DOI: 10.1186/alzrt194  0.88
2013 Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. Journal of Medicinal Chemistry. 56: 2246-55. PMID 23437776 DOI: 10.1021/jm301280p  0.88
2012 Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid ß-amyloid-degrading protease. Molecular Neurodegeneration. 7: 46. PMID 22986058 DOI: 10.1186/1750-1326-7-46  0.88
2012 Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harbor Perspectives in Medicine. 2: a006379. PMID 22675659 DOI: 10.1101/cshperspect.a006379  0.88
2012 Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? Journal of Alzheimer's Disease : Jad. 29: 329-40. PMID 22232014 DOI: 10.3233/JAD-2011-111472  0.88
2011 Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. Plos One. 6: e20818. PMID 21695259 DOI: 10.1371/journal.pone.0020818  0.88
2010 Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. The American Journal of Pathology. 177: 311-24. PMID 20522652 DOI: 10.2353/ajpath.2010.090915  0.88
2010 Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. Plos One. 5: e10504. PMID 20498699 DOI: 10.1371/journal.pone.0010504  0.88
2010 Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging (American Journal of Pathology (2010), 177, (311-324)) American Journal of Pathology. 177: 2146. DOI: 10.2353/ajpath.2010.100772  0.88
2009 Delledonne A, Kouri N, Reinstatler L, Sahara T, Li L, Zhao J, Dickson DW, Ertekin-Taner N, Leissring MA. Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme. Molecular Neurodegeneration. 4: 39. PMID 19835587 DOI: 10.1186/1750-1326-4-39  0.88
2009 Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiology of Disease. 36: 293-302. PMID 19660551 DOI: 10.1016/j.nbd.2009.07.021  0.88
2009 Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh LA, Cuny GD, Stein RL, Selkoe DJ, Leissring MA. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. Plos One. 4: e5274. PMID 19384407 DOI: 10.1371/journal.pone.0005274  0.88
2008 Leissring MA. The AbetaCs of Abeta-cleaving proteases. The Journal of Biological Chemistry. 283: 29645-9. PMID 18723506 DOI: 10.1074/jbc.R800022200  0.88
2008 Neant-Fery M, Garcia-Ordoñez RD, Logan TP, Selkoe DJ, Li L, Reinstatler L, Leissring MA. Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proceedings of the National Academy of Sciences of the United States of America. 105: 9582-7. PMID 18621727 DOI: 10.1073/pnas.0801261105  0.88
2008 Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiology of Disease. 31: 442-50. PMID 18602473 DOI: 10.1016/j.nbd.2008.06.001  0.88
2008 Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castaño EM. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis. The Journal of Biological Chemistry. 283: 17039-48. PMID 18411275 DOI: 10.1074/jbc.M706316200  0.88
2007 Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. The Journal of Biological Chemistry. 282: 25453-63. PMID 17613531 DOI: 10.1074/jbc.M701590200  0.88
2007 Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. The American Journal of Pathology. 171: 241-51. PMID 17591969 DOI: 10.2353/ajpath.2007.070105  0.88
2007 Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. The Journal of Biological Chemistry. 282: 7825-32. PMID 17244626 DOI: 10.1074/jbc.M609168200  0.88
2007 Leissring M, Saido TC. Aβ degradation Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. 157-178. DOI: 10.1007/978-0-387-35135-3_10  0.88
2006 Leissring MA. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Current Alzheimer Research. 3: 431-5. PMID 17168642 DOI: 10.2174/156720506779025206  0.88
2006 Leissring MA, Selkoe DJ. Structural biology: enzyme target to latch on to. Nature. 443: 761-2. PMID 17051198 DOI: 10.1038/nature05210  0.88
2005 Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 44: 6513-25. PMID 15850385 DOI: 10.1021/bi0476578  0.88
2004 Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. The Biochemical Journal. 383: 439-46. PMID 15285718 DOI: 10.1042/BJ20041081  0.88
2004 Bishop G, Coleman P, Crutcher K, David D, Kinoshita J, LaFerla F, Leissring M, Shepherd J, Therianos S, Wang R, Wilson A, Zhu M. Live discussion: how the other half lives - or the what, how, and where, of the AbetaPP intracellular domain. Journal of Alzheimer's Disease : Jad. 6: 193-9. PMID 15171221  0.88
2004 Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American Journal of Pathology. 164: 1425-34. PMID 15039230  0.88
2003 Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin R, Mansourian S, et al. Live discussion: Amyloid-β degradation: The forgotten half of Alzheimer's disease Journal of Alzheimer's Disease. 5: 491-497. PMID 14765518  0.88
2003 Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 40: 1087-93. PMID 14687544 DOI: 10.1016/S0896-6273(03)00787-6  0.88
2003 Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, Selkoe DJ. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. The Journal of Biological Chemistry. 278: 37314-20. PMID 12867419 DOI: 10.1074/jbc.M305627200  0.88
2002 Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 99: 6334-9. PMID 11972038 DOI: 10.1073/pnas.082545599  0.88
2002 Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proceedings of the National Academy of Sciences of the United States of America. 99: 4697-702. PMID 11917117 DOI: 10.1073/pnas.072033799  0.88
2001 Leissring MA, LaFerla FM, Callamaras N, Parker I. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiology of Disease. 8: 469-78. PMID 11442355 DOI: 10.1006/nbdi.2001.0382  0.88
2001 Marchant JS, Stutzmann GE, Leissring MA, LaFerla FM, Parker I. Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling. Nature Biotechnology. 19: 645-9. PMID 11433276 DOI: 10.1038/90249  0.88
2000 LaFerla FM, Sugarman MC, Lane TE, Leissring MA. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. Journal of Molecular Neuroscience : Mn. 15: 45-59. PMID 11211236 DOI: 10.1385/JMN:15:1:45  0.88
2000 Leissring MA, Yamasaki TR, Wasco W, Buxbaum JD, Parker I, LaFerla FM. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proceedings of the National Academy of Sciences of the United States of America. 97: 8590-3. PMID 10900016 DOI: 10.1073/pnas.97.15.8590  0.88
2000 Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. The Journal of Cell Biology. 149: 793-8. PMID 10811821 DOI: 10.1083/jcb.149.4.793  0.88
2000 Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences. 23: 222-9. PMID 10782128 DOI: 10.1016/S0166-2236(00)01548-4  0.88
1999 Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. The Journal of Biological Chemistry. 274: 32535-8. PMID 10551803 DOI: 10.1074/jbc.274.46.32535  0.88
1999 Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. Journal of Neurochemistry. 72: 1061-8. PMID 10037477 DOI: 10.1046/j.1471-4159.1999.0721061.x  0.88
1998 Leissring MA, Sugarman MC, LaFerla FM. Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Drugs & Aging. 13: 193-8. PMID 9789723 DOI: 10.2165/00002512-199813030-00002  0.88
1997 Weber LL, Leissring MA, Yang AJ, Glabe CG, Cribbs DH, LaFerla FM. Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Experimental Neurology. 143: 37-44. PMID 9000444 DOI: 10.1006/exnr.1996.6348  0.88
Show low-probability matches.